This FDA label expansion significantly increases the total addressable market for VYVGART in gMG. Monitor upcoming catalysts including ADAPT OCULUS (ocular MG) and ADAPT Jr (pediatric) readouts, which could further expand the label. Watch for competitive dynamics from UCB's Rystiggo and JNJ's nipocalimab.
ARGX drugs
ARGX drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 11 $813.28entry
- T+1 · 6mo ago 0.00%α +0.14% · $813.28
- T+5 · 6mo ago −4.55%α −4.47% · $776.26
- T+20 · 5mo ago +8.70%α +9.00% · $884.00
- T+60 · 3mo ago +6.72%α +2.33% · $867.94
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
FDA approved label expansion for VYVGART and VYVGART Hytrulo to treat all serotypes of generalized myasthenia gravis (gMG), including anti-MuSK, anti-LRP4, and triple-seronegative patients. The expansion is based on positive Phase 3 ADAPT SERON data and increases the addressable gMG patient population by approximately 20%.
Key Facts
- FDA approved label expansion for VYVGART and VYVGART Hytrulo to cover all gMG serotypes (anti-AChR, anti-MuSK, anti-LRP4, triple seronegative).
- Approval based on Phase 3 ADAPT SERON study (n=119) showing significant improvement in MG-ADL score at week 4 (p=0.0068).
- Expands addressable gMG patients by ~20% (non-AChR-Ab positive patients).
- VYVGART now has the broadest MG label to date.
Financial Impact
Expands addressable market by ~20% in gMG; VYVGART's current annual revenue is ~$2B, expansion could add several hundred million in peak sales.
Risk Factors
- Competition from other FcRn inhibitors (UCB, JNJ).
- Potential pricing/reimbursement pressures.
- Safety signals in broader real-world use.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291372 |
Track record
23 reports on ARGX
6 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +30.22% at T+60 after the Jun 3, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 9, 20267d ago 6-K Bullish 6/10 Entry $962.27 Now $960.04 −0.23% settles Dec 8
- Nov 9, 20267d ago 6-K Neutral 5/10 Entry $962.27 Now $960.04 −0.23% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $962.27 Now $960.04 −0.23% settles Dec 8
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $894.77 Now $960.04 +7.29% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 3/10 Entry $897.85 Now $960.04 +6.93% settles Nov 27
- Oct 22, 202625d ago 6-K Bullish 6/10 Entry $875.76 Now $960.04 +9.62% settles Nov 19
- Oct 19, 202628d ago 6-K Bullish 7/10 Entry $825.61 to $950.95 Now $960.04 +16.28% ▲ +15.18% +18.64% vs SPY
- Oct 8, 20265w ago 6-K Mixed 6/10 Entry $818.63 to $931.38 Now $960.04 +17.27% ▲ +13.77% +19.06% vs SPY
- Sep 29, 20266w ago 6-K Bullish 6/10 Entry $970.66 to $871.52 Now $960.04 −1.09% ▼ −10.21% −10.87% vs SPY
- Sep 10, 20269w ago Institutional Cluster Mixed 5/10 Entry $984.04 to $818.63 Now $960.04 −2.44% ▼ −16.81% −18.93% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers